By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TG Therapeutics, Inc. 

787 Seventh Avenue
48th Floor
New York  New York  10019  U.S.A.
Phone: 212-554-4484 Fax: 212-554-4531


SEARCH JOBS


Industry
Pharmaceutical






Company News
TG Therapeutics, Inc. (MHA) Stock Plunges as Company Modifies Phase III Cancer Trial Protocols 10/14/2016 6:38:28 AM
TG Therapeutics, Inc. (MHA) Launches First Clinical Trial In Multiple Sclerosis (MS) For TG-1101 (Ublituximab) 5/3/2016 7:47:00 AM
TG Therapeutics, Inc. (MHA) Announces Data Presentations For TGR-1202 And TG-1101 In Combination With Ibrutinib At The 57th American Society of Hematology Annual Meeting 12/7/2015 12:24:28 PM
TG Therapeutics, Inc. (MHA) Announces Data Presentations At The 57th American Society of Hematology Annual Meeting From Ongoing Clinical Studies In Patients With Non-Hodgkins Lymphoma (NHL) And Chronic Lymphocytic Leukemia (CLL) 12/7/2015 12:12:51 PM
TG Therapeutics, Inc. (MHA) Recaps Schedule Of Data Presentations At The 57th American Society of Hematology Annual Meeting 12/4/2015 10:48:22 AM
TG Therapeutics, Inc. (MHA) Announces Third Quarter 2015 Financial Results And Business Update 11/9/2015 11:47:28 AM
TG Therapeutics, Inc. (MHA) Announces Data Presentations At The Upcoming 57th American Society of Hematology Annual Meeting 11/5/2015 8:31:22 AM
TG Therapeutics, Inc. (MHA) To Host Conference Call On Third Quarter 2015 Financial Results And Business Update 11/4/2015 10:40:03 AM
TG Therapeutics, Inc. (MHA) To Present At The Ladenburg Thalmann 2015 Healthcare Conference 9/25/2015 7:56:58 AM
TG Therapeutics, Inc. (MHA) Announces Special Protocol Assessment (SPA) Agreement With The FDA For The First Phase 3 Clinical Trial Of Its Proprietary Combination Regimen Of TG-1101 (ublituximab) In Combination With TGR-1202 For Patients With Chronic Lymphocytic Leukemia (CLL) 9/17/2015 6:02:48 AM
12345678910...
//-->